Vanda Pharmaceuticals (NASDAQ:VNDA) Price Target Raised to $20.00 at HC Wainwright

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) had its target price hoisted by stock analysts at HC Wainwright from $18.00 to $20.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the biopharmaceutical company's stock. HC Wainwright's price target suggests a potential upside of 351.47% from the company's current price. HC Wainwright also issued estimates for Vanda Pharmaceuticals' Q1 2025 earnings at ($0.52) EPS, Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.93) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.10 EPS, Q4 2026 earnings at $0.14 EPS and FY2026 earnings at $0.22 EPS.

Separately, StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, February 5th. They issued a "hold" rating on the stock.

Vanda Pharmaceuticals Stock Performance

VNDA traded down $0.06 during mid-day trading on Tuesday, reaching $4.43. 569,122 shares of the stock were exchanged, compared to its average volume of 634,239. The stock has a market capitalization of $258.36 million, a PE ratio of -13.84 and a beta of 0.74. The company has a 50 day moving average price of $4.60 and a two-hundred day moving average price of $4.82. Vanda Pharmaceuticals has a 1 year low of $3.71 and a 1 year high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.06. The firm had revenue of $53.19 million for the quarter, compared to the consensus estimate of $51.00 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. Sell-side analysts expect that Vanda Pharmaceuticals will post -1.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in VNDA. BNP Paribas Financial Markets raised its stake in Vanda Pharmaceuticals by 1,184.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company's stock valued at $292,000 after acquiring an additional 57,393 shares during the period. FMR LLC raised its stake in Vanda Pharmaceuticals by 25.9% in the 3rd quarter. FMR LLC now owns 149,739 shares of the biopharmaceutical company's stock valued at $702,000 after acquiring an additional 30,802 shares during the period. Massachusetts Financial Services Co. MA bought a new stake in Vanda Pharmaceuticals in the 3rd quarter valued at about $864,000. GSA Capital Partners LLP bought a new stake in Vanda Pharmaceuticals in the 3rd quarter valued at about $143,000. Finally, Barclays PLC raised its stake in Vanda Pharmaceuticals by 128.2% in the 3rd quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company's stock valued at $722,000 after acquiring an additional 86,677 shares during the period. 88.14% of the stock is owned by hedge funds and other institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.